Tag: Eversense

BASEL, Switzerland – Ascensia Diabetes Care has successfully completed the initial European launch of the next-generation Eversense E3 CGM System. The benefits of this fully-implantable, long-term CGM system are now available to people with diabetes in all launch markets across Europe in Germany, Switzerland, Poland, Italy, Spain, Norway, Sweden, the Netherlands and Andorra. “We are proud to have successfully brought the Eversense E3 to Europe, where we believe it can make a big difference...

PARSIPPANY, N.J. – Diabetes management is taking a “big leap forward” with the Eversense E3, an implantable continuous glucose monitor, which was recently approved for use up to six months, says Elaine Anderson, head of the Eversense CGM business unit at Ascensia Diabetes Care.  “This is double the lifetime of what people had – you replace it twice (a year),” she said. “It’s not sacrificing accuracy, it’s easy on, easy off so you can take...

PARSIPPANY, N.J. – Ascensia Diabetes Care has launched the next-generation Eversense E3 Continuous Glucose Monitoring System for patients in the U.S., alongside the new Eversense PASS savings program. Eversense E3, which is developed be Senseonics Holdings, was approved for use up to six months by the U.S. Food and Drug Administration earlier this year, making it the longest lasting CGM sensor available in the country. “We are thrilled to offer Eversense E3 to people with diabetes in...

PARSIPPANY, N.J. – Ascensia Diabetes Care has launched the Eversense NOW Remote Monitoring App for the Android Operating System in Europe. The Eversense NOW Remote Monitoring App allows real-time glucose data and alerts from Eversense users to be remotely shared with friends and family. The app allows up to five people to remotely receive updated readings approximately every five minutes, with the ability to easily view recent trends and alerts.  “The value of remote monitoring in...

BASEL, Switzerland – Ascensia Diabetes Care has launched a Patient Assistance Program to reduce out-of-pocket costs for its Eversense Continuous Glucose Monitoring System. “Our fundamental goal at Ascensia is to simplify and improve the lives of people living with diabetes through technologies that facilitate better outcomes and reduce the burden of managing the condition,” said Mary Puncochar, head of Ascensia’s Region US. “We therefore want to be able to offer Eversense...

BASEL, Switzerland - PHC Holdings Corporation and Ascensia Diabetes Care have announced a strategic partnership with Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. As part of the agreement, Ascensia will serve as the exclusive global distribution partner for Senseonics' CGM systems, including Eversense, Eversense XL and future generation products...